Multiple Sclerosis News and Research

Latest Multiple Sclerosis News and Research

Erbitux-based therapy helps in early tumor shrinkage, long-term survival in mCRC patients with KRAS wild-type tumors

Merck Serono, a division of Merck KGaA, Darmstadt, Germany has announced that new data presented today at the 35th Congress of the European Society for Medical Oncology (ESMO) have shown that patients with KRAS wild-type metastatic colorectal cancer (mCRC) who experienced early tumor shrinkage (within 8 weeks) during 1st line Erbitux (cetuximab) based treatment lived a median of 28.3 months.

12 Oct 2010

Merck Serono announces first results from Erbitux BALI-1 study in metastatic triple-negative breast cancer

Merck Serono, a division of Merck KGaA, Darmstadt, Germany, today announced the first results from the BALI-1 study of Erbitux® (cetuximab) in the treatment of metastatic triple-negative breast cancer (TNBC), an aggressive cancer in which early relapse and metastasis are common. The data, presented during the 35th Congress of the European Society for Medical Oncology (ESMO), demonstrate that Erbitux has the potential to improve outcomes for women with this relentlessly devastating cancer.

11 Oct 2010

Prescription Solutions' MS DTM program wins URAC Best Practices Platinum Award

Prescription Solutions, a leading pharmacy benefits management (PBM) organization and a UnitedHealth Group company, received a platinum award in the URAC Best Practices in Health Care Consumer Empowerment and Protection Awards. Prescription Solutions was recognized for its Multiple Sclerosis Disease Therapy Management (MS DTM) program, which empowers patients through education and support to successfully attain skills in self-managing their symptoms and medication therapy for their chronic condition.

11 Oct 2010

Innate Therapeutics initiates MIS416 Phase 2a clinical study in patients with progressive multiple sclerosis

Innate Therapeutics today announced that the company has begun treating patients in a Phase 2a clinical study of its lead molecule, MIS416, in patients with progressive multiple sclerosis (MS).

11 Oct 2010

Cell Cure to receive equity investment of $7.1 million to develop stem cell-based therapies

BioTime, Inc. Cell Cure Neurosciences Ltd., and Hadasit Bio-Holdings Ltd. jointly announced today that Cell Cure will receive an equity investment of $7.1 million from BioTime, Teva Pharmaceutical Industries Ltd., and Hadasit Bio-Holdings (HBL).

11 Oct 2010

Discovery can lead to new approach for treating MS in early stages

A deficiency in one of the immune system's enzymes affects the severity of autoimmune diseases such as MS, and explains why the course of these diseases can vary so much. New findings give an insight into how this enzyme deficiency can be diagnosed, and could lead to new medicines, reveals a thesis from the Sahlgrenska Academy.

11 Oct 2010

Cell Cure, Teva Pharmaceutical enter license option agreement for OpRegen product

BioTime, Inc., Cell Cure Neurosciences Ltd., and Hadasit Bio-Holdings Ltd. jointly announced today that Cell Cure and Teva Pharmaceutical Industries Ltd. have entered into an exclusive license option agreement to develop and commercialize Cell Cure's OpRegen product for the treatment of age-related macular degeneration (AMD).

11 Oct 2010

StemCells provides update on PMD Phase I clinical trial

StemCells, Inc. today provided an update on its ongoing Phase I clinical trial in Pelizaeus-Merzbacher Disease (PMD), a fatal myelination disorder that afflicts male children.

8 Oct 2010

Genzyme board of directors vote to reject tender offer from Sanofi-Aventis

Genzyme Corp. announced today that its board of directors has voted unanimously to reject the unsolicited $69.00 per share tender offer from Sanofi-Aventis, and the board recommends that Genzyme shareholders not tender their shares to Sanofi-Aventis pursuant to the offer.

8 Oct 2010

New video PSA may help raise donation for brain research

In its continuing fight to end brain disorders, the American Academy of Neurology Foundation is turning entries submitted to the 2010 Neuro Film Festival into its latest video public service announcement about the need for donations for more research into curing brain disorders.

7 Oct 2010

Biogen to present late-stage clinical therapies for MS at ECTRIMS Congress

Biogen Idec today announced that more than 45 company and partner-sponsored platform and poster presentations will be presented during the 26th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) in Gothenburg, Sweden, October 13 - 16, 2010.

6 Oct 2010

MRF explores ways to accelerate medical research with online gaming technology

The Myelin Repair Foundation (MRF), a non-profit medical research foundation known for its pioneering Accelerated Research Collaboration (ARC) model, is taking a lesson from online game developers to explore creative ways to accelerate the pace of medical research and shorten the time to market for new medicines.

6 Oct 2010

Mass. hospital sale talks seeking to protect employee retirement plans; Conn. Gov. ask for waiver in preexisting insurance plan

Representatives of Caritas Christi Health Care, the private equity firm seeking to buy it, and the attorney general's office are working on a tentative agreement to protect the retirement plans of 13,000 employees and keep the chain's hospitals open for at least five years.

6 Oct 2010

Neuraltus achieves last patient out for NP001, NP002 studies

Neuraltus Pharmaceuticals, a privately held biopharmaceutical company dedicated to developing and commercializing high-impact therapeutics that address critical unmet needs, primarily in the treatment of neurodegenerative diseases, announced today the Company has achieved last patient out in two studies: a Phase 1 clinical study of NP001 in patients with Amyotrophic Lateral Sclerosis (ALS, or Lou Gehrig's disease) and a Phase 1/2 clinical study of NP002 in patients with L-dopa-induced dyskinesias (muscle movement disorders).

5 Oct 2010

Merck Serono to present Erbitux data at ESMO Congress

Merck Serono, a division of Merck KGaA, Darmstadt, Germany announces today that it will be presenting new data from several studies of Erbitux (cetuximab) in a range of solid tumor types including the first Phase II data in breast and prostate cancers. These data will be presented at the forthcoming 35th European Society for Medical Oncology Congress (ESMO) in Milan, October 8-12, 2010.

5 Oct 2010

Sanofi-aventis commences tender offer for Genzyme acquisition

Sanofi-aventis announced today it has commenced a tender offer for all outstanding shares of common stock of Genzyme Corporation for $69 per share, net to the seller in cash, without interest and less any required withholding taxes. The transaction is valued at approximately $18.5 billion.

4 Oct 2010

Vibrant joins Bike MS NYC to raise money for National Multiple Sclerosis Society

Vibrant will participate in Bike MS NYC on Sunday, October 3 to increase awareness of Multiple Sclerosis and to raise money for the National Multiple Sclerosis Society. The race, hosted by the Southern NY Chapter of the National Multiple Sclerosis Society, will include nearly 6,000 cyclists across two Bike MS NYC locations.

1 Oct 2010

FDA issues Complete Response Letter for Teva's Neutroval BLA

Teva Pharmaceutical Industries Ltd. announced today that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter for the Biologic License Application (BLA) for Neutroval™ (granulocyte colony-stimulating factor) for the reduction in the duration of severe neutropenia and the incidence of febrile neutropenia in patients treated with established myelosuppressive chemotherapy for cancer.

1 Oct 2010

Teva Pharmaceuticals, OncoGenex initiate SYNERGY Phase 3 trial to evaluate custirsen

Teva Pharmaceuticals Industries Ltd. and OncoGenex Pharmaceuticals, Inc. announced today the initiation of SYNERGY, a global Phase 3 trial evaluating custirsen (also known as OGX-011/TV-1011) as first line therapy for the treatment of castrate-resistant prostate cancer (CRPC).

30 Sep 2010

Research shows dexamethasone treatment effective for bacterial meningitis

New research shows that an intravenous (IV) treatment may cut a person's risk of dying from bacterial meningitis. The research is published in the September 29, 2010, online issue of Neurology, the medical journal of the American Academy of Neurology. The treatment is called dexamethasone.

30 Sep 2010

Multiple Sclerosis News and Research

Latest Multiple Sclerosis News and Research

Erbitux-based therapy helps in early tumor shrinkage, long-term survival in mCRC patients with KRAS wild-type tumors

Merck Serono announces first results from Erbitux BALI-1 study in metastatic triple-negative breast cancer

Prescription Solutions' MS DTM program wins URAC Best Practices Platinum Award

Innate Therapeutics initiates MIS416 Phase 2a clinical study in patients with progressive multiple sclerosis

Cell Cure to receive equity investment of $7.1 million to develop stem cell-based therapies

Discovery can lead to new approach for treating MS in early stages

Cell Cure, Teva Pharmaceutical enter license option agreement for OpRegen product

StemCells provides update on PMD Phase I clinical trial

Genzyme board of directors vote to reject tender offer from Sanofi-Aventis

New video PSA may help raise donation for brain research

Biogen to present late-stage clinical therapies for MS at ECTRIMS Congress

MRF explores ways to accelerate medical research with online gaming technology

Mass. hospital sale talks seeking to protect employee retirement plans; Conn. Gov. ask for waiver in preexisting insurance plan

Neuraltus achieves last patient out for NP001, NP002 studies

Merck Serono to present Erbitux data at ESMO Congress

Sanofi-aventis commences tender offer for Genzyme acquisition

Vibrant joins Bike MS NYC to raise money for National Multiple Sclerosis Society

FDA issues Complete Response Letter for Teva's Neutroval BLA

Teva Pharmaceuticals, OncoGenex initiate SYNERGY Phase 3 trial to evaluate custirsen

Research shows dexamethasone treatment effective for bacterial meningitis

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Multiple Sclerosis News and Research

Latest Multiple Sclerosis News and Research

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in